notch1

Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that suppresses HDAC1 activity and induces HDAC2 degradation, exhibiting oral bioavailability. Valproic Acid activates Notch1 signalling and inhibits the proliferation of small cell lung carcinoma cells, making it applicable for research into epilepsy and bipolar disorder.

BMS-906024 (Osugacestat) is an orally available and selective inhibitor of γ-secretase, a small molecule Notch inhibitor.BMS-906024 has broad-spectrum antitumour activity against a variety of human cancer xenografts.BMS-906024 prevents the activation of all four Notch receptors, and is active against Notch1, -2, -3 and -4 receptors. BMS-906024 prevents the activation of all four Notch receptors, with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch1, -2, -3 and -4 receptors, respectively.

Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.

Divalproex Sodium (Valproate semisodium) binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It also is an HDAC inhibitor, Comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex may also work by suppressing repetitive neuronal firing through the inhibition of voltage-sensitive sodium channels.

tCFA15, a trimethyl cyclohexenonic long-chain fatty alcohol with a 15-carbon atom side chain, may regulate Notch signaling and promote neuronal differentiation.

Anti-NOTCH1 Antibody is a human-derived antibody expressed in CHO cells, targeting NOTCH1. It features a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. For its isotype control, refer to HumanIgG2kappa, Isotype Control.

Psoralidin inhibits Akt phosphorylation and phosphatidylinositol 3-kinase activation and transcriptionally. Psoralidin possesses anticancer and chemopreventive properties.

Tangeretin (NSC-618905), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models and was also selected as a Notch-1 inhibitor.

3,5-Bis(4-nitrophenoxy)benzoic acid (Compound W) is a γ-secretase inhibitor that reduces the levels of released Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25).

Notch inhibitor 1 is an effective Notch inhibitor (IC50s: 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively). Notch inhibitor 1 is also used in the research of cancer.

Crenigacestat (LY3039478) is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most tumor cell lines tested. It effectively inhibits mutant Notch receptor activity and, in a xenograft tumor model, inhibits the expression of Notch-regulated genes and N1ICD cleavage in the tumor microenvironment.

Notch1 (Notchhomolog 1, translocation-associated) encodes a protein that is a member of the NOTCH family. This type I transmembrane protein family is characterized by common structural features, including an extracellular domain made up of multiple epidermal growth factor-like (EGF) repeats and an intracellular domain composed of various types of domains.

Notch 1 TFA encodes a member of the NOTCH family of proteins.

(Rac)-SHIN2, a serine hydroxymethyltransferase (SHMT) inhibitor, enhances NOTCH1-driven in vivo survival of primary T-ALL in mice and is useful for studying T-cell acute lymphoblastic leukemia (T-ALL).

CAD204520 functions as an inhibitor of SERCA (IC50 = 0.34 μM), specifically targeting mutations in the wild-type NOTCH1 protein associated with T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL).

NADI-351 is an orally active and potent Notch1 inhibitor that selectively disrupts the Notch1 transcription complex and diminishes its recruitment to target genes. It is utilized in cancer research.

Valproic Acid-d15 is a deuterated compound of Valproic Acid. Valproic Acid has a CAS number of 99-66-1. Valproic Acid is a branched chain fatty acid which potentially enhances central GABAergic neurotransmission and inhibits Na+ channels. Currently, the various molecular mechanisms of action of Valproic Acid have not been completely elucidated. Valproic Acid has been reported to be a potent inhibitor of histone deacetylases (HDACs) in vitro. Valproic Acid is also noted to relieve HDAC-dependent transcriptional repression and causes the hyperacetylation of histones in cultured cells. Additionally, Valproic Acid is reported to activate Wnt-dependent gene expression and to mimic trichostatin A (sc-3511) in the inhibition of histone deacetylase.

Valproic acid-d14 (sodium) is the deuterated form of Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) acts as an HDAC inhibitor, with an IC50 range of 0.5-2 mM, and inhibits the activity of HDAC1 (IC50, 400 μM) while also promoting the degradation of HDAC2. It activates the Notch1 signaling pathway and suppresses the proliferation of small cell lung cancer (SCLC) cells. Additionally, Valproic acid sodium salt is applicable in research related to epilepsy, bipolar disorder, and migraines.

Valproic Acid-d4 is a deuterated compound of Valproic Acid. Valproic Acid has a CAS number of 99-66-1. Valproic Acid is a branched chain fatty acid which potentially enhances central GABAergic neurotransmission and inhibits Na+ channels. Currently, the various molecular mechanisms of action of Valproic Acid have not been completely elucidated. Valproic Acid has been reported to be a potent inhibitor of histone deacetylases (HDACs) in vitro. Valproic Acid is also noted to relieve HDAC-dependent transcriptional repression and causes the hyperacetylation of histones in cultured cells. Additionally, Valproic Acid is reported to activate Wnt-dependent gene expression and to mimic trichostatin A (sc-3511) in the inhibition of histone deacetylase.

2-(Propyl-3,3,3-d3)pentanoic-5,5,5-d3 Acid is a deuterated compound of 2-pentanoic Acid. 2-pentanoic Acid has a CAS number of 99-66-1. Valproic Acid is a branched chain fatty acid which potentially enhances central GABAergic neurotransmission and inhibits Na+ channels. Currently, the various molecular mechanisms of action of Valproic Acid have not been completely elucidated. Valproic Acid has been reported to be a potent inhibitor of histone deacetylases (HDACs) in vitro. Valproic Acid is also noted to relieve HDAC-dependent transcriptional repression and causes the hyperacetylation of histones in cultured cells. Additionally, Valproic Acid is reported to activate Wnt-dependent gene expression and to mimic trichostatin A (sc-3511) in the inhibition of histone deacetylase.

Psoralidin (Standard) is a reference standard for research and analysis in studies involving Psoralidin. Psoralidin inhibits Akt phosphorylation and phosphatidylinositol 3-kinase activation and transcriptionally. Psoralidin possesses anticancer and chemopreventive properties.

Valproic Acid (Standard) is a reference standard for research and analysis in studies involving Valproic Acid. Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that suppresses HDAC1 activity and induces HDAC2 degradation, exhibiting oral bioavailability. Valproic Acid activates Notch1 signalling and inhibits the proliferation of small cell lung carcinoma cells, making it applicable for research into epilepsy and bipolar disorder.